VX-765: Potent, Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a highly selective, orally bioavailable pro-drug that inhibits caspase-1 activity, a key enzyme in the maturation of pro-inflammatory cytokines IL-1β and IL-18 (see APExBIO product information). On oral administration, VX-765 is rapidly converted in vivo to its pharmacologically active form, VRT-043198. This conversion enables the selective inhibition of caspase-1-dependent cytokine release, without impacting other inflammatory mediators such as TNFα or IL-6. The compound is widely used in preclinical research to dissect the mechanisms of inflammasome activation, pyroptosis, and cytokine regulation. Its efficacy is demonstrated in models of rheumatoid arthritis, infectious disease, and skin inflammation (Johnson et al. 2020).

Biological Rationale

Inflammasomes are multi-protein complexes that coordinate the innate immune response to pathogens and danger signals. The canonical inflammasome pathway recruits and activates caspase-1, which in turn cleaves gasdermin D and pro-cytokines such as IL-1β and IL-18, resulting in the secretion of these cytokines and induction of pyroptosis—a lytic, inflammatory form of programmed cell death. This process is central to host defense but can drive pathological inflammation in autoimmune or infectious disease contexts (Johnson et al. 2020).

Selective inhibition of caspase-1 thus provides a targeted approach for modulating inflammasome-driven inflammation, without broadly suppressing immune function. VX-765, by specifically blocking caspase-1, enables researchers to distinguish canonical inflammasome signaling from alternative inflammatory pathways (see related article—this article extends the discussion by detailing new in vivo and cell-type specificity data).

Mechanism of Action of VX-765, Caspase-1 inhibitor, potent and selective

VX-765 is an orally absorbed pro-drug that is metabolized by hepatic and extrahepatic esterases to VRT-043198, its active form. VRT-043198 binds to the active site of caspase-1 (interleukin-1 converting enzyme, ICE), blocking its proteolytic activity. This prevents the cleavage of pro-IL-1β and pro-IL-18 into their mature, secreted forms (Johnson et al. 2020). Importantly, VX-765 displays high selectivity for caspase-1 over related caspases, minimizing off-target effects on apoptosis or other inflammatory pathways (see related article—this article updates selectivity benchmarks with new cytokine data).

In cellular models, VX-765 effectively suppresses the release of IL-1β and IL-18 following inflammasome activation, without significantly impacting cytokines such as IL-6, TNFα, or IL-8. This selectivity enables detailed mechanistic studies of caspase-1-mediated inflammation and pyroptosis inhibition in macrophages and lymphocytes.

Evidence & Benchmarks

• VX-765 blocks caspase-1 activation and the maturation of IL-1β and IL-18 in monocytes and macrophages exposed to canonical inflammasome triggers (Johnson et al. 2020).
• Oral dosing of VX-765 in mice (50–200 mg/kg) significantly reduces joint inflammation and cytokine secretion in rheumatoid arthritis models (APExBIO product information).
• VX-765 prevents CD4 T-cell pyroptotic death in HIV-infected lymphoid tissues in a dose-dependent manner (Johnson et al. 2020).
• In vitro, VX-765 inhibits IL-1β and IL-18 secretion without affecting TNFα or IL-6 in stimulated human monocytes (see related article—this article details distinct cytokine selectivity findings and expands on neuroinflammation models).
• VX-765 is highly soluble in DMSO (≥313 mg/mL) and ethanol (≥50.5 mg/mL with sonication), but insoluble in water; it is stable as a solid at -20°C for long-term storage (APExBIO product information).

Applications, Limits & Misconceptions

VX-765 is used extensively in research on inflammasome-driven diseases, including:

• Autoimmune disorders such as rheumatoid arthritis, where it reduces inflammation and joint pathology.
• Pyroptosis inhibition in macrophages and lymphocytes, allowing mechanistic dissection of cell death pathways (see related article—this article clarifies distinctions between functional genomics and assay-based approaches to VX-765 use).
• HIV research, specifically in the context of CD4 T-cell pyroptosis inhibition.
• Skin inflammation and neuroinflammatory disease models.

However, the compound does not inhibit non-caspase-1-dependent cytokine release or apoptosis. VX-765 is not effective in models where alternative inflammasomes (e.g., NLRP3-independent) or non-canonical cell death pathways predominate. Its utility in human clinical contexts remains investigational.

Common Pitfalls or Misconceptions

• VX-765 does not inhibit apoptotic caspases (e.g., caspase-3, -7, or -9) at pharmacologically relevant concentrations.
• The compound is ineffective against non-canonical inflammasomes (e.g., those activating caspase-4/5/11).
• It does not suppress TNFα, IL-6, or IL-8 secretion, which are regulated independently of caspase-1.
• VX-765 is not water-soluble and must be formulated in DMSO or ethanol for in vitro or in vivo use.
• Long-term solution stability is limited; fresh aliquots are recommended for each experiment.

Workflow Integration & Parameters

• Solubilization: Dissolve VX-765 in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic assistance) for stock solutions; avoid water due to insolubility (product information).
• Storage: Store solid VX-765 desiccated at -20°C; prepare fresh solutions for short-term use.
• In vitro assays: Typical working concentrations range from 1–30 μM; use suc-YVAD-p-nitroanilide as a substrate in caspase-1 activity assays.
• Animal studies: Oral dosing at 50–200 mg/kg/day has shown efficacy in mouse inflammatory models.
• Workflow recommendation: Pre-treat cell cultures or animals 30–60 minutes prior to inflammasome stimulation for optimal inhibition of IL-1β and IL-18 release.

Conclusion & Outlook

VX-765 is a validated, selective caspase-1 inhibitor, enabling precise interrogation of inflammasome-dependent cytokine release and pyroptosis in preclinical models. As a tool compound, it allows researchers to discriminate between canonical and non-canonical inflammatory pathways, supporting advances in autoimmune, neuroinflammatory, and infectious disease research. The ongoing development of VX-765 analogs and clinical translation will benefit from the robust preclinical benchmarks summarized here (Johnson et al. 2020). For detailed product specifications and ordering, refer to VX-765, Caspase-1 inhibitor, potent and selective from APExBIO.